Q1 2026 · 13F-HR
ACUTA CAPITAL PARTNERS, LLCholdings as filed
Filed 2026-05-15 · accession 0001104659-26-062163
$141.8M
Reported value
27
Positions
2026-03-31
Period end
The Brief · ACUTA CAPITAL PARTNERS, LLC · Q1 2026
AI · grounded in 13F
ACUTA CAPITAL PARTNERS, LLC closed its position in CIDARA THERAPEUTICS INC, reducing exposure by $19.69M. The fund established new positions in ERAS for $5.74M and IDYA for $2.77M. Other notable activity includes closing positions in JAZZ PHARMACEUTICALS PLC and INSM, while increasing share counts in STRO by 299.44% and MLTX by 223.48%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $27.4M | 19.3% | 84,901 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $26.1M | 18.4% | 495,772 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $11.8M | 8.30% | 3,410,402 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $9.2M | 6.52% | 441,831 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $8.2M | 5.76% | 111,996 | Common | SOLE |
| 869367201 | STRO | SUTRO BIOPHARMA INC | $6.7M | 4.73% | 269,425 | Common | SOLE |
| 29479A108 | ERAS | ERASCA INC | $5.7M | 4.05% | 354,575 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $5.0M | 3.55% | 172,847 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $5.0M | 3.54% | 592,108 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $4.5M | 3.17% | 849,076 | Common | SOLE |
| 603380205 | NERV | MINERVA NEUROSCIENCES | $4.3M | 3.02% | 709,500 | Common | SOLE |
| 61559X104 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $3.6M | 2.52% | 191,760 | Common | SOLE |
| 04016X101 | ARGX | ARGEN SE - ADR | $3.4M | 2.42% | 4,690 | Common | SOLE |
| H5870P102 | OCS | OCULIS HOLDING AG | $2.6M | 1.84% | 98,339 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $2.5M | 1.79% | 26,069 | Common | SOLE |
| 35104E104 | — | 4D MOLECULAR THERAPEUTICS INC | $2.3M | 1.59% | 242,255 | Common | SOLE |
| 03237H101 | AMLX | AMYLYX PHARMACEUTICALS INC | $2.1M | 1.48% | 151,067 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $2.0M | 1.39% | 439,464 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $1.6M | 1.13% | 48,234 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $1.6M | 1.10% | 145,900 | Common | SOLE |
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $1.3M | 0.93% | 2,224 | Common | SOLE |
| 45166A102 | IDYA | IDEAYA BIOSCIENCES INC | $1.2M | 0.82% | 350 | CALL | SOLE |
| 29384C108 | TRDA | ENTRADA THERAPEUTICS INC | $1.1M | 0.80% | 89,358 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $907,863 | 0.64% | 60,808 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $713,143 | 0.50% | 28,919 | Common | SOLE |
| 578784100 | MAZE | MAZE THERAPEUTICS INC | $577,150 | 0.41% | 19,335 | Common | SOLE |
| 90466Y202 | UNCY | UNICYCIVE THERAPEUTICS INC | $381,370 | 0.27% | 57,959 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.